Fenamole is a muscle relaxant. It is effectively inhibits muscle spasms at good levels for a four hours and at significant levels for six hours. Clinical benefits were derived in patients with spasticity-spasm for periods up to 24 hours after a single oral dose. Fenamole is relatively free of adverse side effects particularly in the central nervous system. It is a potent copper chelator. It was once investigated as a potential antirheumatic agent in man.

Tetroquinone (Tetrahydroxy-1,4-benzoquinone, tetrahydroxy-p-benzoquinone, tetrahydroxybenzoquinone) is cyclohexadiene derivative with four hydroxyl groups and two ketone groups in opposite (para) positions, with potent prooxidant activity. The exposure of exponentially growing cultures to Tetroquinone, in the presence of Ca2+, caused a dose-dependent inhibition of cell growth and DNA synthesis. The chemical reactivity of Tetroquinone is strongly similar to those of physiological polyphenols, such as catechols and catecholamines. Despite their physiological and pharmacological roles, these compounds may, in addition, present toxicological properties due to their ability to autoxidize generating ROS and quinones Similar to catechols, the OH-substituents confer to Tetroquinone the ability to autoxidize readily in neutral aqueous solutions generating intermediate superoxide anion radicals, semiquinone radicals, and the corresponding quinone. The compound can be synthesized from glyoxal or from myo-inositol (phytic acid), a natural compound widely present in plants.

Hydroxystenozole is an orally active anabolic-androgenic steroid (AAS) that was described in the literature in 1967 but was never marketed.

Brocresine, an aromatic L-amino acid decarboxylase inhibitor with both a peripheral and central action was shown to potentiate the therapeutic effect of levodopa in Parkinson's disease.

Sulfazamet is a sulfanilamide derivative that exhibits antibacterial activity against Streptococci sepsis

Doretinel is a member of a class of compounds known collectively as retinoids. As a topical gel, it was being studied for its potential use as a dermatological product.

Sulofenur is an orally active diarylsulfonylurea derivative patented by American pharmaceutical company Eli Lilly and Co. as an antitumor agent. In preclinical studies, Sulofenur exhibits significant activity against advanced colon adenocarcinoma xenografts intrinsically resistant to virtually all standard chemotherapeutic agents and also had very significant activity against several pediatric tumors grown as xenografts. Clinically, Sulofenur was disappointing, and although some responses were reported in phase I trials this was not confirmed for ovarian cancer in the phase II setting. Toxicity in man was due mainly to methemoglobinemia and anemia, which limited the concentrations of drug that could be achieved to levels well below those shown to elicit a therapeutic response in the xenograft models.